// App-Quantinova.ai

P077 : Updated Safety Analysis of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis

Researchers

Presenter

  • Stuart D Cook

Principal Investigators

  • Gavin Giovannoni

  • Thomas P Leist

  • Sana Syed

  • Axel Nolting

  • Doris Damian

  • Regina Schick

Medical Centers

  • Rutgers, The State University of New Jersey, New Jersey Medical School Newark NJ United States

  • Queen Mary University of London and Blizard Institute Barts and The London School of Medicine and Dentistry London United Kingdom

  • Thomas Jefferson University, Philadelphia, PA

  • EMD Serono Research & Development Institute, Inc., Rockland, MA

  • Merck KGaA, Darmstadt, Germany

Locations

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • Aldo-Keto Reductase Family 1 Member B

Drug/Treatment

  • Cladribine

Outcome

  • N/A

Study Design

  • Placebo Control

  • Cohort

Phase

  • NA

Study Id's

  • NCT00213135

  • NCT00641537

  • NCT00725985

  • NCT01013350

Sponsors

  • EMD Serono Inc

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved